Montelino Therapeutics LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor variant 7 (AR-v7)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.